Zobrazeno 1 - 10
of 1 459
pro vyhledávání: '"Fred SAAD"'
Autor:
Francesco Chierigo, Rocco Simone Flammia, Gabriele Sorce, Benedikt Hoeh, Lukas Hohenhorst, Andrea Panunzio, Zhe Tian, Fred Saad, Marcus Graefen, Michele Gallucci, Alberto Briganti, Francesco Montorsi, Felix K.H. Chun, Shahrokh F. Shariat, Alessandro Antonelli, Giovanni Guano, Guglielmo Mantica, Marco Borghesi, Nazareno Suardi, Carlo Terrone, Pierre I. Karakiewicz
Publikováno v:
Current Urology, Vol 18, Iss 2, Pp 128-132 (2024)
Abstract. Objectives. This study aimed to test the association between of type and number of D'Amico high-risk criteria (DHRCs) with cancer-specific mortality (CSM) in high-risk prostate cancer patients treated with radical prostatectomy. Materials a
Externí odkaz:
https://doaj.org/article/63acf018d2eb4171ba4db35d7818dd58
Autor:
Okyaz Eminaga, Fred Saad, Zhe Tian, Ulrich Wolffgang, Pierre I. Karakiewicz, Véronique Ouellet, Feryel Azzi, Tilmann Spieker, Burkhard M. Helmke, Markus Graefen, Xiaoyi Jiang, Lei Xing, Jorn H. Witt, Dominique Trudel, Sami-Ramzi Leyh-Bannurah
Publikováno v:
npj Imaging, Vol 2, Iss 1, Pp 1-12 (2024)
Abstract Malignancy grading of prostate cancer (PCa) is fundamental for risk stratification, patient counseling, and treatment decision-making. Deep learning has shown potential to improve the expert consensus for tumor grading, which relies on the G
Externí odkaz:
https://doaj.org/article/c4b8543e519440bb95cf3c3b228ab60d
Autor:
Kim N. Chi, Steven M. Yip, Glenn Bauman, Stephan Probst, Urban Emmenegger, Christian K. Kollmannsberger, Patrick Martineau, Tamim Niazi, Frédéric Pouliot, Ricardo Rendon, Sebastien J. Hotte, David T. Laidley, Fred Saad
Publikováno v:
Current Oncology, Vol 31, Iss 3, Pp 1400-1415 (2024)
Prostate-specific membrane antigen (PSMA) is highly expressed in prostate cancer and a therapeutic target. Lutetium-177 (177Lu)-PSMA-617 is the first radioligand therapy to be approved in Canada for use in patients with metastatic castration-resistan
Externí odkaz:
https://doaj.org/article/64b195e581c7483cb8fda268b1214380
Autor:
Okyaz Eminaga, Fred Saad, Zhe Tian, Ulrich Wolffgang, Pierre I. Karakiewicz, Véronique Ouellet, Feryel Azzi, Tilmann Spieker, Burkhard M. Helmke, Markus Graefen, Xiaoyi Jiang, Lei Xing, Jorn H. Witt, Dominique Trudel, Sami-Ramzi Leyh-Bannurah
Publikováno v:
npj Imaging, Vol 2, Iss 1, Pp 1-1 (2024)
Externí odkaz:
https://doaj.org/article/6e50e8000ef34e08b3aaca7284d9f850
Autor:
Mattia L. Piccinelli, Stefano Tappero, Cristina Cano Garcia, Francesco Barletta, Reha-Baris Incesu, Simone Morra, Lukas Scheipner, Zhe Tian, Stefano Luzzago, Francesco A. Mistretta, Matteo Ferro, Fred Saad, Shahrokh F. Shariat, Sascha Ahyai, Nicola Longo, Derya Tilki, Alberto Briganti, Felix K.H. Chun, Carlo Terrone, Ottavio de Cobelli, Gennaro Musi, Pierre I. Karakiewicz
Publikováno v:
European Urology Open Science, Vol 53, Iss , Pp 109-115 (2023)
Background: Guidelines recommend VENUSS and GRANT models for the prediction of cancer control outcomes after nephrectomy for nonmetastatic papillary renal cell carcinoma (pRCC). Objective: To test the ability of VENUSS and GRANT models to predict 5-y
Externí odkaz:
https://doaj.org/article/f675564d985b40d3beecc31ba1c796f2
Autor:
Karen Gambaro, Mélanie Groleau, Suzan McNamara, Arif Awan, Maged Salem, Mahmoud Abdelsalam, Eve St-Hilaire, François Vincent, Julie Carrier, Helen MacKay, Louise Provencher, Dominique Boudreau, Zineb Hamilou, Fred Saad, Cristiano Ferrario, Gerald Batist, Maud Marques
Publikováno v:
Journal of Pharmacy & Pharmaceutical Sciences, Vol 26 (2023)
There is an increasing demand for real-world data pertaining to the usage of cancer treatments, especially in settings where no standard treatment is specifically recommended. This study presents the first real-world analysis of third-line treatment
Externí odkaz:
https://doaj.org/article/feab0871603e4619976a4a6c0af8c91a
Autor:
Rocco Simone Flammia, Benedikt Hoeh, Francesco Chierigo, Lukas Hohenhorst, Gabriele Sorce, Zhen Tian, Costantino Leonardo, Markus Graefen, Carlo Terrone, Fred Saad, Shahrokh F. Shariat, Alberto Briganti, Francesco Montorsi, Felix K. H. Chun, Michele Gallucci, Pierre I. Karakiewicz
Publikováno v:
Current Urology, Vol 16, Iss 4, Pp 191-196 (2022)
Abstract. Background. The National Comprehensive Cancer Network (NCCN) guidelines recommend pelvic lymph node dissection (PLND) in NCCN high- and intermediate-risk prostate cancer patients. We tested for PLND nonadherence (no-PLND) rates within the S
Externí odkaz:
https://doaj.org/article/a56c9b8e0d404091b331323e993e7f0f
Autor:
Benedikt Hoeh, Rocco Simone Flammia, Lukas Hohenhorst, Gabriele Sorce, Andrea Panunzio, Stefano Tappero, Zhe Tian, Fred Saad, Michele Gallucci, Alberto Briganti, Carlo Terrone, Shahrokh F. Shariat, Markus Graefen, Derya Tilki, Alessandro Antonelli, Marina Kosiba, Philipp Mandel, Luis A. Kluth, Andreas Becker, Felix K.H. Chun, Pierre I. Karakiewicz
Publikováno v:
European Urology Open Science, Vol 44, Iss , Pp 94-101 (2022)
Background: Survival data regarding cytoreductive nephrectomy (CN) in metastatic renal cell carcinoma (mRCC) patients according to the type and extent of tumor-associated vascular thrombus are scarce. Objective: To test for survival differences in mR
Externí odkaz:
https://doaj.org/article/bed1421e61804985ae8feda55f489758
Autor:
Shawn Malone, Christopher J. D. Wallis, Richard Lee‐Ying, Naveen S. Basappa, Ilias Cagiannos, Robert J. Hamilton, Ricardo Fernandes, Cristiano Ferrario, Geoffrey T. Gotto, Scott C. Morgan, Christopher Morash, Tamim Niazi, Krista L. Noonan, Ricardo Rendon, Sebastien J. Hotte, Fred Saad, Anousheh Zardan, Brendan Osborne, Katherine F. Y. Chan, Bobby Shayegan
Publikováno v:
BJUI Compass, Vol 3, Iss 5, Pp 383-391 (2022)
Abstract Objectives To describe patterns of practice of PSA testing and imaging for Ontario men receiving continuous ADT for the treatment of non‐metastatic castration‐resistant prostate cancer (nmCRPC). Patients and Methods This was a retrospect
Externí odkaz:
https://doaj.org/article/3f6b6dfc44aa41928642415c19d064c2
Autor:
Celestia S. Higano, Daniel J. George, Neal D. Shore, Oliver Sartor, Kurt Miller, Peter S. Conti, Cora N. Sternberg, Fred Saad, Juan Pablo Sade, Joaquim Bellmunt, Matthew R. Smith, Kumari Chandrawansa, Per Sandström, Frank Verholen, Bertrand Tombal
Publikováno v:
EClinicalMedicine, Vol 60, Iss , Pp 101993- (2023)
Summary: Background: Radium-223, a targeted alpha therapy, is approved to treat bone-dominant metastatic castration-resistant prostate cancer (mCRPC), based on significantly prolonged overall survival versus placebo and a favourable safety profile in
Externí odkaz:
https://doaj.org/article/ede8b4395fd74aa190c82bdfe489b529